Integra LifeSciences Holdings Corporation

Integra LifeSciences Holdings Corporation is a global medical technology company headquartered in Princeton, New Jersey, founded in 1989. The company's mission is to innovate treatment pathways to advance patient outcomes and set new standards of care, dedicated to limiting uncertainty for surgeons so they can focus on providing optimal patient care.

Integra LifeSciences offers a broad portfolio of devices, implants, and biomaterials across two primary segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). The CSS segment focuses on technologies and instruments for neurosurgery, neurocritical care, and otolaryngology. The TT segment concentrates on complex wound surgery, surgical reconstruction, and peripheral nerve repair, utilizing regenerative technologies, surgical instruments, and advanced wound care products.

In recent leadership news, Stuart M. Essig was appointed President and Chief Executive Officer, effective May 1, 2026, succeeding Mojdeh Poul, while also continuing as Chairman of the Board. Michael McBreen was also appointed Chief Commercial Officer. The company recently reported earnings and revenue that surpassed market expectations and showcased its neurosurgery and tissue reconstruction portfolio at the Truist Securities MedTech Conference 2026, with investors acknowledging the new leadership's efforts in operational execution despite ongoing discussions regarding quality and recall issues.